Lithium Long COVID Dose-finding Study
NCT06108297 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5
Last updated 2024-10-22
Summary
This open-label study will assess if lithium dosages of 30-45mg/day are associated with greater symptomatic benefit than dosages of 10-15mg/day previously assessed among 50 patients with long COVID.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
Lithium
Elemental lithium as lithium aspartate.
Sponsors & Collaborators
-
State University of New York at Buffalo
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-12
- Primary Completion
- 2024-03-26
- Completion
- 2024-05-02
Countries
- United States
Study Locations
More Related Trials
-
Long COVID-19 and MAB Study
NCT05508295 ·Status: UNKNOWN
-
Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19
NCT04924829 ·Status: UNKNOWN
-
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
NCT04409262 ·Status: COMPLETED ·Phase: PHASE3
-
Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
NCT04359706 ·Status: COMPLETED
-
Lymphocyte to Procalcitonin Ratio in Covid-19 Patients
NCT06620159 ·Status: ACTIVE_NOT_RECRUITING
-
Tocilizumab in Covid-19 Penumonia in Buenos Aires City
NCT05057962 ·Status: COMPLETED
-
Co-infection Management in COVID-19 Critically Ill
NCT04382092 ·Status: COMPLETED ·Phase: NA
-
Long-term Impact of Infection With Novel Coronavirus (COVID-19)
NCT04362150 ·Status: RECRUITING
-
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia
NCT04361032 ·Status: UNKNOWN ·Phase: PHASE3
-
Pneumococcal Carriage in Patients With Lower Respiratory Tract Infection (LRTI)
NCT01861184 ·Status: COMPLETED
-
Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID
NCT06597396 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Ceftobiprole in Hospital Acquired Pneumonia
NCT00229008 ·Status: COMPLETED ·Phase: PHASE3
-
Model to Predict Coinfection in Elderly Patients With COVID-19
NCT06321367 ·Status: COMPLETED
-
Investigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis
NCT06977165 ·Status: NOT_YET_RECRUITING
-
Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP
NCT01662258 ·Status: WITHDRAWN ·Phase: NA
-
A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
NCT00111644 ·Status: COMPLETED ·Phase: PHASE2
-
Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients
NCT04674410 ·Status: WITHDRAWN
-
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
NCT06669403 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Long-term Symptomatic Follow-up of Patients with Long COVID Syndrome
NCT06879535 ·Status: ACTIVE_NOT_RECRUITING
-
Leflunomide in Mild COVID-19 Patients
NCT04361214 ·Status: TERMINATED ·Phase: PHASE1
-
Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab
NCT04359667 ·Status: UNKNOWN
-
Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults
NCT01940731 ·Status: UNKNOWN ·Phase: PHASE2
-
NAC for Attenuation of COVID-19 Symptomatology
NCT05074121 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory Infection
NCT06175611 ·Status: RECRUITING
-
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)
NCT04317092 ·Status: UNKNOWN ·Phase: PHASE2